Definitive Contract 75N93020C00016
Award Date
7/1/20
Potential Completion Date
8/31/26
Potential Value
$44M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Venatorx Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Malvern, PA 19355, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a Cost Plus Fixed Fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Venatorx Pharmaceuticals Inc., a biopharmaceutical company, for the development of an orally bioavailable β-lactam/β-lactamase inhibitor combination for biodefense and public health. The contract, valued at $48,773,738.76, supports the advancement of new antibiotics to treat drug-resistant gram-negative...
The Defense Threat Reduction Agency awarded a $19,969,099.47 cost-plus-fixed-fee definitive contract to Venatorx Pharmaceuticals Inc. (doing business as Venatorx) for the research, development, and manufacturing of penicillin binding proteins. The contract does not have a set-aside designation and has a completion date of October 27, 2023. Venatorx, a for-profit organization, has a history of receiving federal contracts and grants from agencies such as the Department of Health and Human...
The U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $318,625,321.00 cost-plus-fixed-fee contract to Venatorx Pharmaceuticals Inc. for the development of an antibiotic to treat infections caused by biothreat pathogens such as Yersinia pestis, Francilla tularensis, and Burkholderia pseudomallei. This contract, which has a period of performance through September 2032, was not set aside for any particular business...
This is a federal contract award made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services (HHS), to Venatorx Pharmaceuticals Inc., a biopharmaceutical company specializing in the discovery and development of novel anti-infective therapeutics. The contract, valued at $147,481,537.00, does not have a set-aside designation and was awarded as a definitive, cost-sharing contract. The work under this contract...
This is a $30,704,925.57 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Achaogen, Inc., a for-profit organization. The contract was awarded on September 1, 2008, with a period of performance through August 27, 2016, and was not set aside for any specific business type.
The contract was awarded under a Broad Agency Announcement (BAA) solicitation, BAA...
This is a $7,621,277 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Microbiotix, Inc., a clinical-stage biopharmaceutical company. The contract is for the development of phenoxyacetamide T3SS inhibitors as adjunctive agents to antibacterial therapy for multidrug-resistant Pseudomonas aeruginosa infections. This contract is not set aside for any specific...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $18,523,063 definitive cost-plus-fixed-fee contract to Blacksmith Medicines, Inc. (also doing business as Forge Therapeutics) to develop an LPXC inhibitor for the treatment of multidrug-resistant gram-negative urinary tract infections. This work will be performed in San Diego, California over 14 months. There is no set-aside designation associated with this contract....
This $17,818,012 definitive cost-reimbursement contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to AN2 Therapeutics, Inc. for the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant (AMR) bacterial biothreat pathogens. The contract was issued under NIAID's Omnibus Broad Agency Announcement No. HHS-NIH-NIAID-BAA2021-1, which solicited proposals across three...
This is a definitive cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Basilea Pharmaceutica International Ltd, a biopharmaceutical company based in Switzerland. The $85,175,444 contract supports the clinical development of BAL30072, a novel monosulfactam antibiotic for treating infections caused by multidrug-resistant gram-negative bacterial pathogens. This contract is not set...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, has awarded a $27,032,719.27 cost-plus-fixed-fee contract to Spero Therapeutics, Inc. to advance the clinical and non-clinical development of an antibiotic candidate. This contract is not set aside and does not reference a larger contract vehicle. The award is in support of NIAID's mission to develop vaccines, therapeutics, and medical diagnostics for the prevention,...